Chapter 5: Triglyceride-lowering treatment in adults.
出版信息
Kidney Int Suppl (2011). 2013 Nov;3(3):284-285. doi: 10.1038/kisup.2013.37.
Abstract
摘要
相似文献
1
Chapter 5: Triglyceride-lowering treatment in adults.第5章：成人降甘油三酯治疗
Kidney Int Suppl (2011). 2013 Nov;3(3):284-285. doi: 10.1038/kisup.2013.37.
2
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.载脂蛋白脂蛋白脂酶基因 Triglyceride-Lowering LPL 变异体与 LDL 受体基因 LDL-C-Lowering LDLR 变异体与冠心病风险的相关性研究。
JAMA. 2019 Jan 29;321(4):364-373. doi: 10.1001/jama.2018.20045.
3
Chapter 6: Triglyceride-lowering treatment in children.第6章：儿童降甘油三酯治疗
Kidney Int Suppl (2011). 2013 Nov;3(3):286. doi: 10.1038/kisup.2013.38.
4
Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hypertriglyceridemic individuals: studies before and after triglyceride-lowering therapy.高甘油三酯血症个体体内脂肪分解刺激后小而高密度脂蛋白颗粒的产生：降甘油三酯治疗前后的研究
Metabolism. 1998 Feb;47(2):234-42. doi: 10.1016/s0026-0495(98)90227-x.
5
Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment.脂蛋白脂肪酶基因中的常见序列变异赋予了非诺贝特治疗对甘油三酯的反应。
Pharmacogenomics. 2009 Feb;10(2):267-76. doi: 10.2217/14622416.10.2.267.
6
Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.阿托伐他汀和洛伐他汀在啮齿类动物中的降脂活性：大鼠甘油三酯降低与低密度脂蛋白动物模型中的疗效相关。
Atherosclerosis. 1995 Oct;117(2):237-44. doi: 10.1016/0021-9150(95)05576-i.
7
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.甘油三酯、动脉粥样硬化与心血管结局研究：聚焦于ω-3脂肪酸
Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7.
8
Triglyceride-lowering agents.降低甘油三酯的药物。
Bioorg Med Chem. 2014 Jul 15;22(14):3551-64. doi: 10.1016/j.bmc.2014.05.008. Epub 2014 May 13.
9
Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501.新型胰岛素增敏剂JTT-501的降甘油三酯作用
Eur J Pharmacol. 1999 May 28;373(1):85-91. doi: 10.1016/s0014-2999(99)00256-3.
10
Current perspectives on the management of hypertriglyceridemia.高甘油三酯血症管理的当前观点
Am Heart J. 2000 Aug;140(2):232-40. doi: 10.1067/mhj.2000.108001.
引用本文的文献
1
Cessation of Bezafibrate in patients with chronic kidney disease improves renal function.停止使用苯扎贝特可改善慢性肾脏病患者的肾功能。
Sci Rep. 2020 Nov 13;10(1):19768. doi: 10.1038/s41598-020-76861-1.
2
Lipid abnormalities in kidney disease and management strategies.肾脏疾病中的脂质异常及管理策略。
World J Nephrol. 2015 Feb 6;4(1):83-91. doi: 10.5527/wjn.v4.i1.83.
本文引用的文献
1
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.调脂治疗与胰腺炎风险：荟萃分析。
JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439.
2
New fibrate use and acute renal outcomes in elderly adults: a population-based study.新的贝特类药物使用与老年人群的急性肾结局：一项基于人群的研究。
Ann Intern Med. 2012 Apr 17;156(8):560-9. doi: 10.7326/0003-4819-156-8-201204170-00003.
3
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.长期非诺贝特治疗 2 型糖尿病伴肾功能损害患者的获益和安全性：FIELD 研究。
Diabetes Care. 2012 Feb;35(2):218-25. doi: 10.2337/dc11-1109. Epub 2011 Dec 30.
4
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.辛伐他汀联合依折麦布降低慢性肾脏病患者 LDL 胆固醇的效果（心脏和肾脏保护研究）：一项随机安慰剂对照试验。
Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.
5
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.更强化降低 LDL 胆固醇的疗效和安全性：来自 26 项随机试验中 170000 名参与者数据的荟萃分析。
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
6
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.非诺贝特对 2 型糖尿病患者肾功能的影响：非诺贝特干预和糖尿病事件降低（FIELD）研究。
Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4.
7
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.贝特类药物对心血管结局的影响：系统评价和荟萃分析。
Lancet. 2010 May 29;375(9729):1875-84. doi: 10.1016/S0140-6736(10)60656-3. Epub 2010 May 10.
8
Effects of combination lipid therapy in type 2 diabetes mellitus.2 型糖尿病的联合降脂治疗效果。
N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14.
9
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.长期非诺贝特治疗对9795例2型糖尿病患者心血管事件的影响（FIELD研究）：随机对照试验
Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2.
10
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).在一项针对2型糖尿病的安慰剂对照研究中，非诺贝特在3年内减少了微量白蛋白尿的进展：糖尿病动脉粥样硬化干预研究（DAIS）的结果。
Am J Kidney Dis. 2005 Mar;45(3):485-93. doi: 10.1053/j.ajkd.2004.11.004.
Zotero 插件